Measles Virus Antibody Responses in Children Randomly Assigned to Receive Standard-Titer Edmonston-Zagreb Measles Vaccine at 4.5 and 9 Months of Age, 9 Months of Age, or 9 and 18 Months of Age
Measles Virus Antibody Responses in Children Randomly Assigned to Receive Standard-Titer Edmonston-Zagreb Measles Vaccine at 4.5 and 9 Months of Age, 9 Months of Age, or 9 and 18 Months of Age
复制标题
DOI：
10.1093/infdis/jiu117
复制
发表时间：
2014-09-01
影响因子：
6.4
通讯作者：
Aaby, Peter
中科院分区：
文献类型：
--
作者：
Martins, Cesario;Garly, May-Lill;Aaby, Peter
世界卫生组织建议低收入国家在9个月大时接种麻疹疫苗。我们在4.5、9、18和24个月大时检测了麻疹病毒抗体应答，这些儿童被随机分配到4.5和9个月大、9个月大或9和18个月大时接受标准滴度的Edmonston-Zagreb MV。在4.5个月大时，75%的儿童具有非保护性麻疹病毒抗体水平。在4.5月龄时接受MV后，77%（316/408）在9月龄时具有保护性抗体水平;在9月龄时接受第二剂MV后，97%（326/337）在24月龄时具有保护性抗体水平。此外，9月龄和24月龄的反应与接受第一剂MV时的抗体水平呈负相关，9月龄时接受的第二剂MV为抗体水平低的儿童提供了抗体水平的显著提高。在318名9个月大时接受MV的儿童中，在18个月大时有或没有第二次剂量，99%（314）在24个月大时具有保护水平。在4.5和9月龄接受MV的组中，24月龄时的几何平均滴度显著低于9月龄接受MV的组（P = .0001）。总之，在几乎所有儿童中，早期2剂MV方案与24个月龄时的麻疹病毒抗体保护水平相关。
The World Health Organization recommends administration of measles vaccine (MV) at age 9 months in low-income countries. We tested the measles virus antibody response at 4.5, 9, 18, and 24 months of age for children randomly assigned to receive standard-titer Edmonston-Zagreb MV at 4.5 and 9 months, at 9 months, or at 9 and 18 months of age. At 4.5 months of age, 75% had nonprotective measles virus antibody levels. Following receipt of MV at 4.5 months of age, 77% (316/408) had protective antibody levels at 9 months of age; after a second dose at 9 months of age, 97% (326/337) had protective levels at 24 months of age. In addition, the response at both 9 and 24 months of age was inversely correlated with the antibody level at receipt of the first dose of MV, and the second dose of MV, received at 9 months of age, provided a significant boost in antibody level to children who had low antibody levels. In the group of 318 children who received MV at 9 months of age, with or without a second dose at 18 months of age, 99% (314) had protective levels at 24 months of age. The geometric mean titer at 24 months of age was significantly lower in the group that received MV at 4.5 and 9 months of age than in the group that received MV at 9 months of age (P = .0001). In conclusion, an early 2-dose MV schedule was associated with protective measles virus antibody levels at 24 months of age in nearly all children.